Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation by Kim, Jeong Hun et al.
Decursin inhibits retinal neovascularization via suppression of
VEGFR-2 activation
Jeong Hun Kim,1 Jin Hyoung Kim,1 You Mie Lee,2 Eun-Mi Ahn,3 Kyu-Won Kim,4 Young Suk Yu1
1Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Department of Ophthalmology, College of Medicine, Seoul
National University and Seoul Artificial Eye Center Clinical Research Institute, Seoul National University Hospital, Seoul, Korea;
2Department of Natural Sciences, School of Life Sciences and Biotechnology, Kyungpook National University, Daegu, Korea;
3Department of Herbal Foodceutical Science, Daegu Hanny University, Daegu, Korea; 4Neurovascular Coordination Research
Center, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea
Purpose: Pathologic angiogenesis in the retina leads to the catastrophic loss of vision. Retinopathy of prematurity (ROP),
a vasoproliferative retinopathy, is a leading cause of blindness in children. We evaluated the inhibitory effect of decursin
on retinal neovascularization.
Methods: Anti-angiogenic activity of decursin was evaluated by vascular endothelial growth factor (VEGF)-induced
proliferation, migration, and in vitro tube formation assay of human retinal microvascular endothelial cells (HRMECs).
We also used western blot analysis to assess inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2)
phosphorylation by decursin. After intravitreal injection of decursin in a mouse model of ROP, retinal neovascularization
was examined by fluorescence angiography and vessel counting in cross-sections. The toxicity of decursin was evaluated
through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in HRMECs as well as histologic
and immunohistochemistry examination for glial fibrillary acidic protein in the retina.
Results: Decursin significantly inhibited VEGF-induced proliferation, migration, and the formation of capillary-like
networks of retinal endothelial cells in a dose-dependent manner. Decursin inhibited VEGF-induced phosphorylation of
VEGFR-2, blocking the VEGFR-2 signaling pathway. When intravitreously injected, decursin dramatically suppressed
retinal neovascularization in a mouse model of ROP. Even in a high concentration, decursin never induced any structural
or inflammatory changes to cells in retinal or vitreous layers. Moreover, the upregulation of glial fibrillary acidic protein
expression was not detected in Mueller cells.
Conclusions: Our data suggest that decursin may be a potent anti-angiogenic agent targeting the VEGFR-2 signaling
pathway, which significantly inhibits retinal neovascularization without retinal toxicity and may be applicable in various
other vasoproliferative retinopathies as well.
Angiogenesis plays a central role in tissue development
and repair. A balance of many stimulating or inhibiting factors
tightly  regulate  these  processes  [1].  However,  when  that
balance is disrupted, stimulation with angiogenic factors, such
as vascular endothelial growth factor (VEGF) and fibroblast
growth  factor  (FGF),  allows  vascular  endothelial  cells  to
proliferate and migrate into the surrounding tissue. These
newly formed, dysfunctional blood vessels are leaky, fragile
and prone to rupture, and hemorrhagic, a condition that is
associated  with  fibrous  proliferation  [2].  Therefore,
pathologic angiogenesis in the retina leads to retinal edema,
retinal or vitreous hemorrhage, and finally tractional retinal
detachment, which can result in catastrophic loss of vision
[3]. Pathologic angiogenesis is the major cause of vision loss
at all ages, including retinopathy of prematurity (ROP) in
Correspondence to: Young Suk Yu, Department of Ophthalmology,
College of Medicine, Seoul National University and Seoul Artificial
Eye Center Clinical Research Institute, Seoul National University
Hospital,  Seoul  151-744,  Republic  of  Korea;  Phone:
82-2-2072-3492; FAX: 82-2-741-3187; email: ysyu@snu.ac.kr
children, diabetic retinopathy (DR) in young adults, and age-
related macular degeneration (AMD) in the elderly [4].
ROP  is  a  leading  cause  of  blindness  in  children  [5].
Although  the  cellular  and  molecular  processes  remain
incompletely  understood,  ROP  is  known  to  be  a
vasoproliferative retinopathy in premature infants that occurs
through  vaso-obliteration  followed  by  pathologic
angiogenesis in developing retinal vasculature [6]. Therefore,
oxygen-induced retinopathy (OIR) in a mouse model, which
reflects the current understanding of the pathogenesis of the
disease, is based on hyperoxia-induced vaso-obliteration of
capillaries in mouse pups and their subsequent return to room
air. This triggers retinal angiogenesis, starting from the inner
retina and characterized by growing into the vitreous [7].
In  ROP,  retinal  neovascularization  followed  by  vaso-
obliteration appears to be driven by relative tissue hypoxia.
Increased VEGF production in response to hypoxia leads to
pathologic  retinal  angiogenesis.  VEGF  and  the  VEGFR
system are known to be the main regulators of angiogenesis,
in which VEGF interacts with the high-affinity tyrosine kinase
receptors  VEGFR-1  and  VEGFR-2  [8].  In  particular,
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1868VEGFR-2  signaling  is  essential  not  only  for  vascular
endothelial  proliferation  but  also  for  cell  migration  or
morphogenesis, including tube formation. For angiogenesis,
VEGFR-2  efficiently  activates  the  phospholipase-Cγ  and
protein kinase C pathways, and its downstream c-Raf-MEK-
MAP kinase pathway, which is mainly regulated by a single
autophosphorylation of 1175-tyrosine [9,10].
Angelica gigas Nakai has been traditionally known as a
medicinal plant in East Asia. Decursin, isolated from the root
of  this  plant  [11],  has  been  reported  to  have  variable
pharmacologic  qualities,  such  as  neuroprotection  [12],
antibacterial properties [13], and anticancer activities [14,
15]. In the course of our research regarding new angiogenesis
inhibitors from natural products, we recently found decursin
to be a potent angiogenesis inhibitor: It effectively inhibited
tumor  angiogenesis  as  well  as  VEGF-induced  angiogenic
processes  in  vitro  and  in  vivo,  including  proliferation,
migration,  and  tube  formation  of  human  umbilical-vein
endothelial  cells  and  neovascularization  in  chick
chorioallantoic membrane [16]. In addition, we demonstrated
that  decursin  inhibits  VEGF-induced  phosphorylation  of
VEGFR-2 and its signaling pathway [16].
In  our  study,  we  showed  that  decursin  significantly
inhibits  retinal  neovascularization  via  suppression  of
VEGFR-2 activation. Decursin significantly inhibited VEGF-
induced  proliferation  of  human  retinal  microvascular
endothelial cells (HRMECs) in a dose-dependent manner,
which  could  be  related  to  suppression  of  VEGFR-2
phosphorylation  and  effectively  inhibited  VEGF-induced
migration and tube formation of HRMECs. In addition, when
decursin  was  intravitreally  injected,  retinal
neovascularization  in  OIR  was  significantly  suppressed.
Interestingly, in quantities of up to 50 μM, which is five times
the effective therapeutic concentration [16], decursin never
affected  the  viability  of  HRMECs.  Moreover,  decursin
induced neither the activation of Mueller cells, which are
thought  to  play  an  important  role  both  structurally  and
functionally in the retina [17], nor any structural change.
METHODS
Extraction of decursin: The roots (Professor Eun-Mi Ahn,
Daegu Hanny University, Daegu, Korea) of Angelica gigas
Nakai  (Umbelliferae  family)  were  extracted  serially  with
methanol,  ethyl  acetate,  and  N-butanol,  and  fractionated.
From the ethyl acetate fraction, decursin was isolated using
silica-gel  column  chromatography.  After  column
chromatography,  the  structure  of  purified  decursin  was
characterized by gas chromatography (GC; Shimadzu, Kyoto,
Japan), nuclear magnetic resonance (JEOL JNM-LA 400; Jeol
Ltd.,  Tokyo,  Japan),  and  mass  spectroscopy  (JEOL-AX
505WA; Jeol Ltd.). As our previous report [16], decursin was
isolated from the ethylacetate fraction using silica gel column
chromatography.  After  column  chromatography,  decursin
(C19H20O5)  with  a  molecular  weight  of  328  was
characterized.
Animals:  Eight  weeks  old  C57BL/6  mice  were  kept  in
standard 12 h dark-light cycles and approximately 23 °C room
temperature. C57BL/6 mice were purchased from Samtako
(Daejeon, Korea). Care, use, and treatment of all animals in
this study were in strict agreement with the Association for
Research in Vision and Ophthalmology Statement for the Use
of Animals in Ophthalmic and Vision Research.
Cell culture: HRMECs were purchased from Cell systems
(Kirkland,  WA)  and  grown  on  attachment  factor–coated
plates in complete medium (Cell Systems, Kirkland, WA) or
in M199 medium supplemented with 20% fetal bovine serum,
3 ng/ml basic FGF (Millipore, Bedford, MA), and 10 U/ml
heparin (Sigma, St. Louis, MO). HRMECs used in this study
were taken from passages four to six.
Proliferation  assay  with  [3H]-thymidine:  HRMECs  were
seeded in gelatin-coated 48-well plates at 1×104 cells per well.
Cells  were  treated  with  20  ng/ml  VEGF  or  1  to  50  μM
decursin. After 24 h, 0.5 µCi per well of [3H]-thymidine was
added, and the plates were incubated for 16 h. Cells were fixed
with methanol, washed with distilled water, treated with 5%
trichloroacetic  acid,  and  solubilized  with  0.3  N  sodium
hydroxide. HRMECs were fixed with two 20 min applications
of 80% methanol and treated with two 10-min application 5%
trichloroacetic  acid.  Cell-associated  radioactivity  was
determined  by  liquid  scintillation  counter  (Perkin  Elmer,
Waltham, MA).
Western blot analysis: HRMECs were seeded in 100-mm
dishes (5×105 cells) and were incubated for 12 h in either
5 μM decursin or 20 ng/ml VEGF. The cell lysates were
separated by 12.5% sodium dodecyl sulfate PAGE, followed
by transfer to polyvinylidene fluoride membranes (Millipore)
using standard electroblotting procedures. Blots were then
blocked  and  immunolabeled  overnight  at  4  °C  with  the
primary  antibodies,  anti-VEGFR-2,  antiphosphorylated
VEGFR-2 (Cell Signaling Technology, Beverly, MA) and
anti-β-actin  (Upstate  Biotechnology,  Lake  Placid,  NY).
Immunolabeling  was  detected  with  an  enhanced
chemiluminescence  kit  (Amersham  Life  Science,
Buckinghamshire,  UK),  using  the  manufacturer’s
instructions.
Scratch wound migration assay on retinal endothelial cells:
Cell migration was evaluated with scratch wound migration
assay modified from our previous description [18]. HRMECs
(1×105 cells) were plated onto gelatin-coated culture dishes at
90% confluence and were wounded with a razor blade. Wound
was made by scraping across with the razor blade. After the
wounding,  plates  were  rinsed  with  a  serum-free  medium.
Then  the  wounded  monolayers  were  incubated  in  10  μM
decursin or 20 ng/ml VEGF (Sigma) for 12 h. The cells were
fixed  with  absolute  methanol  and  stained  with  Giemsa
solution (BDH Laboratory Supplies, London, UK). Cells were
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Japan)  and  photographed  at  a  magnification  of  200×.
Migration was determined by counting the number of cells
that moved beyond the reference line in randomly selected
fields.
Tube  formation  assay  on  retinal  endothelial  cells:  Tube
formation was assayed as per our previous description [19].
HRMECs (1×105 cells) were inoculated on the surface of
Matrigel  basement  membrane  matrix  (BD  Biosciences,
Franklin Lakes, NJ) and treated with 10 μM decursin or 20
ng/ml VEGF (Sigma) for 18 h. The morphologic changes of
the  cells  and  tubes  formed  were  observed  under  a  light
microscope and photographed at a magnification of 200×.
Tube formation was quantified by counting the number of
connected cells in randomly selected fields at a magnification
of 200× and dividing that number by the total number of cells
in the same field.
Oxygen-induced retinopathy: OIR was induced as described
by Smith et al. [7], with some modifications [20-22]. Briefly,
newborn mice were randomly assigned to experimental and
control groups. At postnatal day (P) 7, five to seven pups in
the  experimental  group  were  exposed  to  hyperoxia  (75%
±0.5%  O2)  for  five  days  (P7–P11)  and  then  returned  to
normoxia  (room  air)  for  five  days.  Neovascularization
occurred on return to normoxia and peaked at P17. To assess
the anti-angiogenic activity of decursin, we intravitreously
injected the pups with 5 µM decursin in 1 µl phosphate-
buffered  saline  on  P14,  when  retinal  neovascularization
began. There were at least 10 animals in each group.
Qualitative  assessment  of  retinal  neovascularization  by
fluorescence  angiography:  As  we  noted  in  our  previous
description [20-22], at P17, deeply anesthetized mice were
perfused through the tail vein with fluorescein-conjugated
dextran  (molecular  weight  500,000;  Sigma)  dissolved  in
phosphate-buffered  saline  (PBS;  137mM  NaCl,  10mM
phosphate, 2.7mM KCl, pH 7.4). After 1 h of perfusion, the
eyes were enucleated and fixed in 4% paraformaldehyde for
2  h.  The  retinas  were  dissected,  flat-mounted  in  Dako
mounting medium (DakoCytomation, Glostrup, Denmark),
and viewed by fluorescence microscopy (BX50; Olympus,
Tokyo, Japan) at a magnification of 4×.
Quantitative  assessment  of  retinal  neovascularization  by
counting  vascular  lumens:  As  we  noted  in  our  previous
description [20-22], at P17, the eyes were removed, fixed in
4% paraformaldehyde for 24 h, and embedded in paraffin.
Sagittal sections of 5 µm, each 30 µm apart, were cut through
the  cornea  parallel  to  the  optic  nerve.  The  sections  were
stained with hematoxylin and eosin to allow assessment of
retinal vasculature via light microscopy. Any vascular lumens
on  the  vitreal  side  of  the  inner  limiting  membrane  were
counted  in  at  least  10  sections  from  each  eye  by  two
independent observers blind to treatment (Jeong Hun Kim and
Jin Hyoung Kim). The average number of intravitreal vessels
per section was calculated for each group.
Histologic examination and immunohistochemistry: We gave
six 8-week-old C57BL/6J mice an intravitreal injection of
50 µM decursin, which is five times the effective therapeutic
concentration. Seven days later, the mice were euthanized by
CO2 by inhalation and their eyes were enucleated. Enucleated
globes  were  fixed  in  4%  paraformaldehyde  for  24  h  and
embedded in paraffin. Sagittal sections of 5 µm, each 30 µm
apart, were cut through the cornea parallel to the optic nerve.
The sections were stained with hematoxylin and eosin, and
histologic examination was performed via light microscopy
by  magnification  of  400×.  For  immunohistochemistry  for
glial  fibrillary  acidic  protein  (GFAP),  sections  were
deparaffinized  and  hydrated  by  sequential  immersion  in
xylene and graded alcohol solutions. Sections were treated
with proteinase K for 5 min at 37 °C and then treated for 10
min with normal serum obtained from the same species in
which  the  secondary  antibody  was  developed  to  block
nonspecific staining. Slides were incubated overnight at 4 °C
with 1:100 anti-GFAP (Dako, San Francisco, CA), and 1:400
fluorescein  isothiocyanate–conjugated  immunoglobulin  G
(Santa Cruz Biotechnology, Santa Cruz, CA) was used as a
secondary antibody. The slides were mounted and observed
with fluorescence microscopy. The excitation and emission
wavelengths were 495 nm and over 515 nm.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide  assay:  Cell  viability  was  evaluated  with  3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide
(MTT) assay. HRMECs (1×105 cells) were plated in 96 well
plates and cultured overnight. Cells were treated with 1 to
100 µM decursin for 48 h. The medium was then replaced with
fresh  medium  containing  0.5  mg/ml  MTT,  and  the  cells
remained in place for 4 h. After incubation, the medium was
carefully removed from the plate, and dimethyl sulfoxide was
added to solubilize formazan produced from MTT by the
viable cells. Absorbance was measured at 540 nm using a
microplate reader (Molecular Devices, Sunnyvale, CA).
Statistical  analysis: Statistical  differences  between  groups
were evaluated with the Student’s unpaired t-test (two-tailed).
Values provided here are means±SD. A p value ≤0.05 was
considered significant.
RESULTS
Decursin inhibits VEGF-induced proliferation of HRMECs by
blocking VEGFR-2 phosphorylation: To investigate the effect
of  decursin  on  VEGF-induced  proliferation  of  retinal
endothelial cells, we used 1–50 µM concentrations of decursin
on HRMECs. With the treatment of VEGF, proliferation of
HRMECs increased 1.98 fold compared with control, which
was significantly inhibited by cotreatment with decursin in a
dose-dependent manner (Figure 1A).
We next addressed how decursin could block VEGF-
induced proliferation of HRMECs. Because we recently found
that decursin inhibits proliferation of endothelial cells induced
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1870by VEGF via inhibition of the VEGFR-2 signaling pathway
[16], we investigated the effect of decursin on VEGFR-2
phosphorylation. At 5 min after VEGF treatment, VEGF-
induced  phosphorylation  of  VEGFR-2  was  significantly
increased; however, it was effectively blocked by cotreatment
with decursin (Figure 1B).
Decursin  inhibits  VEGF-induced  migration  and  tube
formation  of  HRMECs:  To  evaluate  the  anti-angiogenic
activity  of  decursin  on  in  vitro  angiogenesis  induced  by
VEGF, we performed a scratch wound assay for migration and
tube  formation  assay  of  HRMECs.  First,  we  addressed
whether  decursin  could  inhibit  VEGF-induced  migration.
With the treatment of VEGF, the migration of HRMECs was
enhanced 3.5 fold compared with the control, whereas the
migratory ability was nearly eliminated by decursin, similar
to the control (Figure 2A).
Next, to investigate the effect of decursin on the VEGF-
induced maturation of migrated retinal endothelial cells, we
evaluated tube network formation. In treatment with VEGF,
formation of the capillary-like networks of HRMECs was
extensive—a  rate  1.8  fold  that  of  control  cells—but  was
completely inhibited by cotreatment with decursin (Figure
2B).
Decursin  inhibits  retinal  neovascularization  in  oxygen-
induced retinopathy: To investigate whether decursin could
reduce retinal neovascularization, we injected 10 µM decursin
intravitreously  on  P14  in  OIR,  and  qualitatively  and
quantitatively  analyzed  the  anti-angiogenic  activity  of
decursin on retinal neovascularization. First, to investigate the
anti-angiogenic  activity  of  decursin  on  retinal
neovascularization  in  OIR,  we  performed  fluorescence
angiography. On P17 in OIR, many neovascular tufts at the
border of vascularized and nonvascularized retina were easily
detected (Figure 3A), whereas they were significantly reduced
in decursin-treated mice (Figure 3B).
Next, we quantitatively determined the anti-angiogenic
activity  of  decursin  on  retinal  neovascularization.  As  our
previous description [20-22], vascular lumens on the vitreal
side between the posterior capsule of the lens and the inner
limiting membrane were counted. Compared with the lumens
in control OIR mice (Figure 3C), the neovascular lumens in
decursin-treated  mice  were  dramatically  decreased  in  the
number of lumens (Figure 3D). Compared with neovascular
lumens in control mice (19±1.5), those in decursin-treated
mice were significantly reduced (6.5±1.2; p<0.05; Figure 3E).
Decursin induced no cytotoxicity in retinal endothelial cells
and  no  retinal  toxicity:  To  determine  whether  decursin
induces  cytotoxicity  in  retinal  endothelial  cells,  HRMEC
viability was evaluated at doses ranging from 1 to 100 µM
decursin.  As  shown  in  Figure  4A,  no  cytotoxicity  was
observed  for  decursin,  even  at  amounts  of  up  to  50  µM
decursin, five times its therapeutic concentration [16].
To  investigate  the  retinal  toxicity  of  decursin,  we
performed histologic and immunohistochemistry studies for
Figure  1.  Decursin  inhibits  VEGF-
induced migration and tube formation of
HRMECs.  A:  Human  retinal
microvascular  endothelial  cells
(HRMECs) were treated with 20 ng/ml
vascular  endothelial  growth  factor
(VEGF) or 1–50 µM decursin for 24 h.
A  cell-proliferation  assay  with  [3H]-
thymidine was performed. Each value
represents  the  mean  (±SD)  of  three
independent experiments. The asterisk
indicates a p<0.05. B: HRMECs were
treated with 20 ng/ml VEGF or 10 µM
decursin  for  5  min.  Western  blot
analysis using phospho- (p-)VEGFR-2
and vascular endothelial growth factor
receptor-2 (VEGFR-2) antibodies was
performed, with β-actin serving as the
loading control. Figures were selected
as  representative  data  from  three
independent experiments. Quantitative
analysis was performed by measuring
the intensity relative to the control. Each
value  represents  means±SEM  from
three  independent  experiments.  The
asterisk indicates a p<0.05. The size of
scale bars in figure A, B were 100 µm.
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1871Figure  2.  Decursin  inhibits  VEGF-
induced migration and tube formation of
HRMECs.  A:  Human  retinal
microvascular  endothelial  cells
(HRMECs)  were  plated  onto  gelatin-
coated culture dishes and wounded with
a  razor  blade.  Wound  was  made  by
scraping  across  with  the  razor  blade.
The wounded monolayers were treated
with incubation in 10 µM decursin or 20
ng/ml  vascular  endothelial  growth
factor (VEGF) for 12 h. Figures were
selected  as  representative  data  from
three  independent  experiments.
Migration was quantified by counting
the number of cells that moved beyond
the reference line. The basal migration
of  HRMECs  that  were  left  without
decursin and VEGF were normalized to
100%. Each value represents the mean
(±SD)  of  three  independent
experiments.  The  asterisk  indicates  a
p<0.05. B: HRMECs were inoculated
on  the  surface  of  the  basement
membrane matrix and treated with 10
µM decursin or 20 ng/ml VEGF for 18
h.  Figures  were  selected  as
representative  data  from  three
independent  experiments.  The  basal
tube  formation  of  HRMECs  without
decursin and VEGF was normalized to
100%. Each value represents the mean
(±SD)  of  three  independent
experiments.  The  asterisk  indicates  a
p<0.05.
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1872GFAP in the retina, following intravitreal injection of 50 µM
of  decursin.  There  were  neither  structural  changes  nor
inflammatory  cells  in  any  retinal  layers  or  in  vitreous.
Moreover, upregulation of GFAP expression was not detected
in Müller cells, which are structurally and functionally critical
in the retina (Figure 4B).
DISCUSSION
We demonstrated that decursin significantly inhibits retinal
neovascularization  in  OIR  without  retinal  toxicity.  These
results were supported by findings that decursin significantly
inhibits  VEGF-induced  proliferation,  migration,  and  tube
formation  of  retinal  endothelial  cells.  As  supported  by
findings in our recent report, the anti-angiogenic activity of
decursin in retinal neovascularization was closely related to
inhibition of VEGFR-2 activation in retinal endothelial cells
[16].
In the pathogenesis of retinal neovascularization in ROP,
increased VEGF expression in the retina, followed by oxygen-
induced vessel loss and subsequent hypoxia, leads to retinal
neovascularization [6,7]. Therefore, VEGF plays a critical
role  in  retinal  neovascularization  in  ROP,  which  can  be
directly supported by data from previous reports showing that
inhibition  of  VEGF  significantly  decreases  retinal
neovascularization in OIR [23,24]. In addition to the direct
inhibition  of  VEGF,  the  regulation  of  hypoxia-inducible
factor  1α  (HIF-1α),  a  key  transcriptional  complex  of
angiogenic growth factors such as VEGF and platelet-derived
growth factor, also could be crucial in control of pathologic
angiogenesis  [25],  possibilities  well  supported  by  our
previously reported findings. We have reported that specific
histone deacetylase inhibition may suppress the VEGF gene
in  an  indirect  manner  by  downregulating  HIF-1α  with
increasing  p53  and  von  Hippel-Lindau  levels  in  hypoxic
conditions  [26],  a  process  that  was  effectively  applied  to
retinal  neovascularization  [22].  Moreover,  we  found  that
VEGF  expression  was  inhibited  by  the  destabilization  of
HIF-1α protein via significantly reduced binding of heat shock
protein 90 [27], a process that was also applied to retinal
neovascularization  [21].  Because  VEGFR-2  is  the  major
signal  transducer  for  angiogenesis  processes  [2],  the
VEGFR-2  signaling  pathway  represents  a  good  target  for
therapeutic intervention [28]. Recently, we also suggested that
decursin inhibits VEGF-mediated angiogenesis by blocking
the VEGFR-2 signaling pathway [16]. Decursin, isolated from
Angelica gigas Nakai, is a coumarin compound with various
Figure  3.  Decursin  inhibits  retinal
neovascularization  in  oxygen-induced
retinopathy. A, B: Retinal vasculature in
control mice and decursin-treated mice
with oxygen-induced retinopathy (OIR)
was  evaluated  by  fluorescence
angiography  using  fluorescein-
conjugated  dextran.  Whole-mount
retinal preparation from postnatal day
17  (P17)  control  mice  (A)  and  mice
subjected to OIR and treated with 10 µM
decursin (B) was performed after 1 h of
perfusion  with  fluorescein-conjugated
dextran.  Arrows  indicate  neovascular
tufts  of  intravitreous
neovascularization.  Figures  were
selected  as  representative  data  from
three  independent  experiments  with
similar results. Scale bars equal 50 µm.
Hematoxylin-stained  cross-sections
were prepared from P17 control mice
(C)  and  mice  subjected  to  OIR  and
treated  with  10  μM  of  decursin  (D).
Arrows indicate the vascular lumens of
new vessels growing into the vitreous.
Figures were selected as representative
data  from  three  independent
experiments with similar results. Scale
bars  equal  100  µm.  E:  Each  value
represents  the  mean  (±SD)  of  three
independent experiments. The asterisk
indicates a p<0.05.
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1873biologic activities [12-14]. The proposed molecular targets for
those activities include the protein kinase C pathway [14],
which  is  efficiently  activated  in  VEGFR-2–mediated
angiogenesis [9,10]. In our current study, we demonstrated
that  decursin  significantly  inhibited  VEGF-induced
proliferation, migration, and tube formation, which is related
to  blocking  VEGFR-2  phosphorylation.  Interestingly,  this
anti-angiogenic activity of decursin in retinal endothelial cells
was effectively applied to retinal neovascularization of OIR,
the mouse model of ROP.
We found that decursin had no retinal toxicity in mice at
doses of up to 50 µM, five times the therapeutically effective
concentration  in  retinal  neovascularization.  Moreover,
decursin never induced the upregulation of GFAP in Müller
cells, which appears to be an indicator of stress in the retina
[29].
Decursin may be a potent anti-angiogenic agent targeting
the VEGFR-2 signaling pathway that significantly inhibits
retinal  neovascularization  without  retinal  toxicity.
Furthermore,  decursin  could  be  applicable  in  various
vasoproliferative  retinopathies,  including  diabetic
retinopathy, age-related macular degeneration, and ROP.
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